SkyePharma, Vectura Ltd. deal

Vectura non-exclusively licensed its Aspirair dry powder inhaler device to SKP for use with certain macromolecules. SKP paid £2 million ($3.7 million) for a 4% stake in Vectura. SKP said Aspirair will...